Is there truly no progression in NMOSD and MOGAD?

被引：0
|
作者：
Lechner-Scott, J. [1 ,2 ]
Giovannoni, G. [3 ]
Ch, Hawkes [3 ]
Levy, M. [4 ,5 ]
Ea, Yeh [6 ]
机构：
[1] John Hunter Hosp, Dept Neurol, Newcastle, Australia
[2] Univ Newcastle, Hunter Med Res Inst, Newcastle, England
[3] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[4] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Neurol, Toronto, ON, Canada
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2025年 / 94卷
关键词：
Progression; NMOSD; MOGAD; Magnetic resonance imaging; Multiple sclerosis; BRAIN ATROPHY; ONSET;
D O I：
10.1016/j.msard.2025.106300
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Association of Disease Characteristics with Utilization of Behavioral Medicine in Patients with NMOSD and MOGAD
    Swetlik, Carol
    Conway, Devon
    Widmar, Julie
    Kunchok, Amy
    Tworek, Grace
    Sullivan, Amy
    Galioto, Rachel
    Aboseif, Albert
    Abbatemarco, Justin
    NEUROLOGY, 2023, 100 (17)
  • [32] COVID-19 infections in NMOSD and MOGAD: a population based study
    Capobianco, M.
    Comi, G.
    Sormani, M. P.
    Patti, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 92 - 92
  • [33] Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore
    Foo, Reuben
    Yau, Christine
    Singhal, Shweta
    Tow, Sharon
    Loo, Jing-Liang
    Tan, Kevin
    Milea, Dan
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2022, 11 (02): : 184 - 195
  • [34] Goals and Design of a Dedicated Tertiary Care Centre NMOSD/MOGAD Clinic
    Burton, Jodie
    Alikhani, Katayoun
    Brust, Tyson
    Costello, Fiona
    Harris, Colleen
    Morrow, Sarah
    NEUROLOGY, 2024, 103 (07) : S3 - S4
  • [35] The neuro-ophthalmological manifestations of NMOSD and MOGAD-a comprehensive review
    Moheb, Negar
    Chen, John J. J.
    EYE, 2023, 37 (12) : 2391 - 2398
  • [36] Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
    Solène Dauby
    Dominique Dive
    Laurence Lutteri
    Cécile Andris
    Isabelle Hansen
    Pierre Maquet
    Emilie Lommers
    Acta Neurologica Belgica, 2022, 122 : 135 - 144
  • [37] Quantitative MRI measures of MOGAD compared to MS, NMOSD and healthy controls
    Kunchok, A.
    Ontaneda, D.
    Abbatemarco, J.
    Cohen, J. A.
    Nakamura, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 424 - 425
  • [38] Targeting B cells to modify MS, NMOSD, and MOGAD Part 2
    Graf, Jonas
    Mares, Jan
    Barnett, Michael
    Aktas, Orhan
    Albrecht, Philipp
    Zamvil, Scott S.
    Hartung, Hans-Peter
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (01):
  • [39] Coping Strategies of NMOSD and MOGAD Affected Persons with a Sociological and Psychological Focus (CoMMOnsense)
    Walz, Anna
    Tkachenko, Daria
    Kretschmer, Julian Reza
    Huemmert, Martin W.
    Zimmermann, Tanja
    Trebst, Corinna
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 411 - 412
  • [40] Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives
    Lorefice, L.
    Cortese, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
12345